{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:21:33Z","timestamp":1777929693265,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,4,15]],"date-time":"2009-04-15T00:00:00Z","timestamp":1239753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,4,15]],"date-time":"2009-04-15T00:00:00Z","timestamp":1239753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Onkologie"],"abstract":"<jats:p>In einem kontrollierten klinischen Versuch wurde die Wirksamkeit von Testololakton, Drostanolon und Nandrolon an 91 Patientinnen mit inkurablem Mammakarzinom verglichen. Nach 4w\u00f6chiger Behandlung und nach weiteren 12 Wochen, in denen zus\u00e4tzlich Cyclophosphamid verabfolgt wurde, lie\u00df sich kein Unterschied in der Wirksamkeit der drei Androgene ermitteln. Die Remissionsraten lagen im Mittel nach 4 Wochen bei 24 % und 16 Wochen bei 46 %.<\/jats:p>","DOI":"10.1159\/000213943","type":"journal-article","created":{"date-parts":[[2009,4,16]],"date-time":"2009-04-16T11:28:57Z","timestamp":1239881337000},"page":"172-174","source":"Crossref","is-referenced-by-count":0,"title":["Zur Androgentherapie des inkurablen Mammakarzinoms Kontrollierter klinischer Versuch: Nandrolon \u2013 Testololakton \u2013 Drostanolon"],"prefix":"10.1159","author":[{"given":"G.","family":"Wolff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Rieche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,4,15]]},"container-title":["Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/213943","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000213943","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:48:15Z","timestamp":1777679295000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000213943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,15]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000213943","archive":["Portico"],"relation":{},"ISSN":["0378-584X","1423-0240"],"issn-type":[{"value":"0378-584X","type":"print"},{"value":"1423-0240","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,15]]}}}